← Back to Search

Brain Stimulation

tDCS + SLT for Post-Stroke Aphasia

N/A
Recruiting
Led By Dana Moser, PhD, CCC-SLP
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Single left hemisphere stroke etiology
Adequate hearing and vision to complete the tasks
Must not have
Co-occurring history of neurological disease/disorder/injury (e.g., traumatic brain injury, right hemisphere stroke, dementia)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after 1st and 2nd treatment phases and at 10 follow up after study completion

Summary

This trial will test if a brain stimulator can help people with aphasia (word retrieval deficits) improve their language skills.

Who is the study for?
This trial is for individuals aged 18-80 who have had a stroke on the left side of their brain at least 6 months ago, resulting in aphasia. They must speak English natively and have good hearing and vision. People with severe comprehension deficits, other neurological diseases or major mental illnesses, conditions not suitable for MRI or tDCS (like seizures), or pregnant women cannot participate.
What is being tested?
The study is examining if using Transcranial Direct Current Stimulation (tDCS) alongside Speech-Language Therapy (SLT) can improve language skills better than SLT alone in people with aphasia after a stroke. It also looks at how the brain changes functionally during this process.
What are the potential side effects?
Possible side effects of tDCS may include mild tingling, itching, or discomfort at the stimulation site; headache; fatigue; nausea; and insomnia. These are generally short-lived and considered to be mild.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had a stroke that affected the left side of my brain.
Select...
I can see and hear well enough to do tasks.
Select...
I am between 18 and 80 years old.
Select...
I am a native English speaker.
Select...
I have difficulty speaking or understanding language after a stroke.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of a brain-related condition or injury.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after 1st and 2nd treatment phases and at 10 follow up after study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after 1st and 2nd treatment phases and at 10 follow up after study completion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in correct naming of nouns on Philadelphia Naming Test.
Secondary study objectives
Change in correct naming of verbs on Action Naming Test

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active tDCS (with Speech-Language Treatment)Active Control1 Intervention
tDCS Stimulation Dose: 1.5 mA for 20-mins
Group II: Sham tDCS (with Speech-Language Treatment)Placebo Group1 Intervention
No tDCS stimulation

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
495 Previous Clinical Trials
150,320 Total Patients Enrolled
1 Trials studying Aphasia
40 Patients Enrolled for Aphasia
Dana Moser, PhD, CCC-SLPPrincipal InvestigatorUniversity of Arkansas

Media Library

Active Transcranial Direct Current Stimulation with SLT (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03929432 — N/A
Aphasia Research Study Groups: Sham tDCS (with Speech-Language Treatment), Active tDCS (with Speech-Language Treatment)
Aphasia Clinical Trial 2023: Active Transcranial Direct Current Stimulation with SLT Highlights & Side Effects. Trial Name: NCT03929432 — N/A
Active Transcranial Direct Current Stimulation with SLT (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03929432 — N/A
~12 spots leftby Aug 2026